From 1 November 2018, Medicare Benefits Schedule (MBS) item 11219 will be amended to allow its use for the diagnosis of all ocular conditions for which a medication is listed on the Pharmaceutical Benefits Scheme for intraocular administration.
Additionally, MBS rebate item 42705 for eligible patients undergoing minimally invasive glaucoma (MIGS) in conjunction with cataract surgery has been increased, and a new MBS item, 42505, will be listed, providing a rebate for patients who require removal or replacement of MIGS devices due to device related complications.
